European Journal of Inflammation (Sep 2022)

Serum cytokine/chemokine profile and clinical/paraclinical data in COVID-19 deceased and recovered patients

  • Bahman Aghcheli,
  • Emad Behboudi,
  • Alijan Tabarraei,
  • Hadi Razavi Nikoo,
  • Abdolhalim Rajabi,
  • Abdolvahab Moradi,
  • Britt Nakstad,
  • Alireza Tahamtan

DOI
https://doi.org/10.1177/1721727X221125436
Journal volume & issue
Vol. 20

Abstract

Read online

Objectives: The induction of an intense immune response and cytokine storm is proposed to be central in the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study evaluated serum cytokine/chemokine profiles, and clinical and paraclinical data of COVID-19 deceased and recovered patients in Iran. Methods: The severity of disease, clinical data, and routine laboratory and inflammatory cytokine/chemokine responses were retrospectively explored in 60 in-hospital patients in northern Iran. Characteristics of those who deceased ( n = 30) were compared to recovered ( n = 30), and associations with serum levels of potential disease regulating pro- and anti-inflammatory mediators were studied. Results: The serum levels of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17, IP-10, MIP1-α, MCP1, RANTES, and TNF-α were upregulated in all COVID-19 patients when compared to healthy and gender-matched individuals ( n = 30). Although with no significant difference between deceased and recovered cases, the serum levels of all cytokines/chemokines tended to be higher in the severely diseased non-surviving patients. Association analyses revealed that all cytokine/chemokine levels (except IL-10) significantly affect the disease outcome. Conclusion: This study provides more evidence for the association of cytokine/chemokine levels with the clinical course and outcome of COVID-19. More studies are needed to consider this measurement as an indicator of disease stage and strategy for treatment.